SEC 13F Intelligence

Managers / Q4 2021 · view latest →

RHO CAPITAL PARTNERS INC

CIK 0001020455 · 152 WEST 57TH STREET, 23RD FLOOR, NEW YORK, NY, 10019 · 212-751-6677

Reported Value
$154M
Q4 2021
Positions
5
Filings on Record
18
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Rho Capital Partners Inc reported $154M in U.S.-listed holdings across 5 positions for Q4 2021.

The portfolio is heavily concentrated: Chargepoint alone accounts for 50.1% of reported value.

Compared with Q3 2021, the fund opened 3 new positions and exited 1.

Portfolio Metrics

Turnover
+2.9%
vs prior filed quarter
Largest Position
+50.1%
Chargepoint
New / Exited
3 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $94MQ1 ’19Q2 ’19: $144MQ3 ’19: $119MQ4 ’19: $132MQ4 ’19Q1 ’20: $99MQ2 ’20: $154MQ3 ’20: $120MQ3 ’20Q4 ’20: $190MQ1 ’21: $1.0BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $179MQ4 ’21: $154MQ1 ’22: $145MQ1 ’22Q2 ’22: $59MQ3 ’22: $63MQ4 ’22: $41MQ4 ’22Q2 ’23: $39MQ3 ’23: $20Mfilingsflow.com

Portfolio Composition

By security type
Other: 53.3%Common Stock: 46.7%
  • Other · 53.3% · $82M
  • Common Stock · 46.7% · $72M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LIVEONE INCNEW+3.72M3.72M+$5M$5M
ONTFON24 INCNEW+00+$0$0
CARA THERAPEUTICS INCNEW+00+$0$0
LIVEXLIVE MEDIA INCSOLD OUT3.72M0$11M$0
NGM BIOPHARMACEUTICALS INCHELD+03.77M$12M$67M
CHARGEPOINT HOLDINGS INCHELD+04.05M$4M$77M
MERSANA THERAPEUTICS INCHELD+0796.5K$3M$5M
SENSEONICS HLDGS INCHELD+0159.6K$115,000$426,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

5 positions
#IssuerClass% PortfolioValueShares
1CHARGEPOINT HOLDINGS INCCOM CL A50.12%$77M4.05M
2NGM BIOPHARMACEUTICALS INCCOM43.30%$67M3.77M
3MERSANA THERAPEUTICS INCCOM3.22%$5M796.5K
4LIVEONE INCCOM3.09%$5M3.72M
5SENSEONICS HLDGS INCCOM0.28%$426,000159.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2023$20M3Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$39M3Aug 8, 202313F-HRchanges · EDGAR ↗
Q4 2022$41M3Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$63M4Nov 4, 202213F-HRchanges · EDGAR ↗
Q2 2022$59M4Aug 1, 202213F-HRchanges · EDGAR ↗
Q1 2022$145M5May 11, 202213F-HRchanges · EDGAR ↗
Q4 2021$154M5Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$179M7Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B7Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.0B7May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$190M5Feb 10, 202113F-HRchanges · EDGAR ↗
Q3 2020$120M5Nov 23, 202013F-HRchanges · EDGAR ↗
Q2 2020$154M5Aug 7, 202013F-HRchanges · EDGAR ↗
Q1 2020$99M5May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M5Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$119M5Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$144M5Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$94M5May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.